Global Patent Index - EP 1161279 A1

EP 1161279 A1 2001-12-12 - TREATMENT OF THROMBOSIS BY COMBINED USE OF A FACTOR XA INHIBITOR AND ASPIRIN, TISSUE PLASMINOGEN ACTIVATOR (TPA), A GPIIB/IIIA ANTAGONIST, LOW MOLECULAR WEIGHT HEPARIN OR HEPARIN

Title (en)

TREATMENT OF THROMBOSIS BY COMBINED USE OF A FACTOR XA INHIBITOR AND ASPIRIN, TISSUE PLASMINOGEN ACTIVATOR (TPA), A GPIIB/IIIA ANTAGONIST, LOW MOLECULAR WEIGHT HEPARIN OR HEPARIN

Title (de)

BEHANDLUNG VON THROMBOSE MIT KOMBINATIONEN AUS FACTOR XA HEMMERN MIT ASPIRIN, GEWEBE-PLASMINOGENAKTIVATOREN (TPA), GPIIB/IIIA ANTAGONISTEN, NIEDERMOLEKULARE HEPARIN ODER HEPARIN

Title (fr)

TRAITEMENT DE LA THROMBOSE AU MOYEN D'UNE COMBINAISON D'UN INHIBITEUR DU FACTEUR XA ET D'ASPIRINE, D'UN ACTIVATEUR TISSULAIRE DU PLASMINOGENE (TPA), D'UN ANTAGONISTE DE GPIIB/IIIA, D'HEPARINE A FAIBLE MASSE MOLECULAIRE OU D'HEPARINE

Publication

EP 1161279 A1 (EN)

Application

EP 00913894 A

Priority

  • US 0006451 W
  • US 12381599 P

Abstract (en)

[origin: WO0053264A1] Provided is a method of treating thrombosis in mammals by administering therapeutically effective amounts of a combination of (i) a Factor Xa inhibitor, and (ii) a compound selected from the group consisting of aspirin, TPA, a GPIIb/IIIa antagonist, low molecular weight heparin and heparin, wherein the dose administered for at least one of (i) and (ii) is a subtherapeutic dose. Preferably, the combination of (i) and (ii) provides a synergistic effect.

IPC 1-7 (main, further and additional classification)

A61P 7/02; A61P 9/12; A61K 31/715; A61K 45/06; A61K 38/49; A61K 38/02; A61K 31/42; A61K 31/60

IPC 8 full level (invention and additional information)

A61K 31/19 (2006.01); A61K 31/42 (2006.01); A61K 31/44 (2006.01); A61K 31/47 (2006.01); A61K 31/60 (2006.01); A61K 31/715 (2006.01); A61K 38/02 (2006.01); A61K 38/49 (2006.01); A61K 45/06 (2006.01); A61P 7/02 (2006.01); A61P 9/12 (2006.01)

CPC (invention and additional information)

A61K 38/02 (2013.01); A61K 31/19 (2013.01); A61K 31/42 (2013.01); A61K 31/44 (2013.01); A61K 31/47 (2013.01); A61K 31/60 (2013.01); A61K 31/715 (2013.01); A61K 38/49 (2013.01); A61K 45/06 (2013.01)

Combination set (CPC)

  1. A61K 38/49 + A61K 31/415
  2. A61K 31/715 + A61K 31/415
  3. A61K 31/60 + A61K 31/415
  4. A61K 31/42 + A61K 31/415
  5. A61K 31/19 + A61K 2300/00
  6. A61K 31/42 + A61K 2300/00
  7. A61K 31/44 + A61K 2300/00
  8. A61K 31/47 + A61K 2300/00
  9. A61K 31/60 + A61K 2300/00
  10. A61K 31/715 + A61K 2300/00
  11. A61K 38/02 + A61K 2300/00
  12. A61K 38/49 + A61K 2300/00

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

EPO simple patent family

WO 0053264 A1 20000914; AU 3525400 A 20000928; AU 766089 B2 20031009; BR 0010381 A 20020205; CA 2361650 A1 20000914; CN 1346292 A 20020424; EA 200100966 A1 20020228; EP 1161279 A1 20011212; IL 144798 D0 20020630; JP 2002538226 A 20021112; NZ 513217 A 20031128; ZA 200106360 B 20020802

INPADOC legal status


2005-11-16 [18D] APPLICATION DEEMED TO BE WITHDRAWN

- Effective date: 20050503

2005-02-02 [17Q] FIRST EXAMINATION REPORT

- Effective date: 20041220

2002-10-02 [RAP1] TRANSFER OF RIGHTS OF AN APPLICATION

- Owner name: BRISTOL-MYERS SQUIBB PHARMA COMPANY

2001-12-12 [17P] REQUEST FOR EXAMINATION FILED

- Effective date: 20011005

2001-12-12 [AK] DESIGNATED CONTRACTING STATES:

- Kind Code of Ref Document: A1

- Designated State(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

2001-12-12 [AX] REQUEST FOR EXTENSION OF THE EUROPEAN PATENT TO:

- Free text: LT PAYMENT 20011005;LV PAYMENT 20011005;RO PAYMENT 20011005;SI PAYMENT 20011005